ReviewJournal of innate immunity2026
Insights into Neutrophil Dysfunction in Inherited Metabolic Disorders.
Review in Journal of innate immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human inborn errors of the phagocyte respiratory burst: Chronic granulomatous disease and beyond.Journal of human immunity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInherited metabolic disorders (IMDs) often manifest with defects in neutrophil development, function, or survival, resulting in recurrent severe infections and elevated morbidity. Although neutropenia and immunodeficiency are frequently underrecognized, they are central to the clinical course of several IMDs. SUMMARY: Advances in human genetics and immunometabolism have elucidated the multifaceted mechanisms linking metabolic abnormalities to impaired innate immunity. This review provides a comprehensive analysis of current understanding regarding the pathophysiology, clinical presentation, and management of IMDs with prominent neutrophil involvement, including glycogen storage disease type Ib, glucose-6-phosphatase catalytic subunit 3 deficiency, glucose-6-phosphate dehydrogenase deficiency, glucose transporter-1 deficiency syndrome, propionic acidemia, methylmalonic acidemias, and Barth syndrome. We discuss how impaired glucose metabolism, redox imbalance, and disrupted mitochondrial metabolism undermine neutrophil homeostasis and effector function, resulting in increased susceptibility to infections, failure to thrive, and, in some cases, life-threatening inflammatory complications. Emerging therapies, ranging from dietary metabolic or pharmacological interventions to experimental gene therapies, are reshaping clinical management of IMDs. KEY MESSAGE: Rare IMDs involving neutrophil dysfunction reveal essential links between metabolism, intracellular trafficking, and innate immunity. Molecular diagnosis is crucial for guiding targeted treatments, preventing infectious complications, and improving outcomes. Defining the precise immunometabolic disturbance in these diseases not only advances clinical care but also deepens our understanding of neutrophil biology in broader infectious and inflammatory contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.